Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
West to Present at Jefferies Investor Conference
West to Present at Jefferies Investor Conference
PR Newswire
LIONVILLE, Pa., June 2
LIONVILLE, Pa., June 2 /PRNewswire-FirstCall/ --
West Pharmaceutical Services, Inc. (NYSE: WST) today announced that Donald E. Morel, Jr., Ph.D., Chairman and Chief Executive Officer, and William Federici, Chief Financial Officer, will attend the Jefferies 2010 Global Life Sciences Conference in New York, NY. Management will present an overview of West's business and outlook on Wednesday, June 9, 2010 at 8:30 AM ET
West Pharmaceutical Services, Inc. (NYSE: WST) today announced that its Board of Directors has approved payment of the third-quarter 2010 cash dividend of $0.16 per share. The dividend will be paid on August 4, 2010 to shareholders of record on July 21, 2010.
West to Host Analyst and Investor Day
West to Host Analyst and Investor Day
PR Newswire
LIONVILLE, Pa., April 26
LIONVILLE, Pa., April 26 /PRNewswire-FirstCall/ --
West Pharmaceutical Services, Inc. (NYSE: WST) announced today that it will host an Analyst and Investor Day for financial analysts and investors on Thursday, May 6, 2010 from 8:00 a.m. to 11:30 a.m. EDT in New York, NY. Members of West's senior management will provide an overview of the company's current markets, operations, and growth opportunities. Presentations will begin at 8:30 a.m. EDT.
For further information or registration, please e-mail john.woolford@westwicke.com, or call 443-213-0506.
A live broadcast of the event will be available at the Company's web site, www.westpharma.com, in the "Investor" section. Please allow extra time prior to the webcast to visit the site and download the streaming media software required to listen to the Internet broadcast. The event will be archived on the Company's web site.
West Pharmaceutical Services, Inc. (NYSE:WST) today announced that its Board of Directors has approved payment of the second-quarter 2010 cash dividend of $0.16 per share. The dividend will be paid on May 5, 2010 to shareholders of record on April 21, 2010
West Announces Fourth Quarter, Full Year 2009 Results
- Quarterly Sales Increase 19.9% - - Adjusted EPS is $0.67 in the quarter, $2.11 for the year 2009 - - 2010 Adjusted EPS Guidance is between $2.19 and $2.39 - - Analyst Conference Call at 9 a.m. Today
Investors
Press Releases
Click here to print this page
West Announces Management Change
LIONVILLE, Pa., Nov. 23 /PRNewswire-FirstCall/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced that the company's Chief Operating Officer Matthew T. Mullarkey has left the company by mutual agreement. Company President and former Chief Operating Officer Steven A. Ellers, 58, will defer his previously announced 2010 retirement in order to provide managerial continuity and support following Mr. Mullarkey's departure.
West to Present at Investor Conference
LIONVILLE, Pa., Nov. 12 /PRNewswire-FirstCall/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced that Donald E. Morel, Jr., Ph.D., Chairman and Chief Executive Officer, and William Federici, Chief Financial Officer, will attend the Lazard Capital Markets 6th Annual Healthcare Conference in New York, NY, and will present an overview of West's business and outlook on Tuesday, November 17, 2009 at 1:40 PM ET.
A copy of the corporate presentation document as well as a live audio webcast of the presentations will be posted on the investor link of the Company's website at http://www.westpharma.com/.
The Company announced plans to restructure certain business operations, which will result in the elimination of approximately 100 jobs, and to re-evaluate certain business initiatives and assets. These will result in total charges in the range of $8.0 million to $10.0 million. Approximately $7.0 million of charges are expected to be included in the Company's reported results for the fourth quarter of 2009. The restructuring is expected to result in annual savings of approximately $6.0 million in 2010 and approximately $8.0 million annually thereafter.
West to Host 2009 Third Quarter Conference Call
West to Host 2009 Third Quarter Conference Call
Oct. 27, 2009 (PR Newswire) --
LIONVILLE, Pa., Oct. 27 /PRNewswire-FirstCall/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced today that it will release 2009 third quarter financial results before the market opens on Tuesday, November 3, 2009 and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. To participate on the call please dial 210-839-8398 or 888-790-3758. The passcode is WST.
A live broadcast of the conference call will be available at the Company's web site, www.westpharma.com, in the "Investor" section. Please allow extra time prior to the call to visit the site and download the streaming media software required to listen to the Internet broadcast.
West Increases Quarterly Dividend to $0.16
LIONVILLE, Pa., Oct. 2 /PRNewswire-FirstCall/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced that its Board of Directors has approved an increase of one cent per share in the Company's quarterly cash dividend, to $0.16 per share, beginning in the fourth quarter of 2009. The 6.7% increase is the seventeenth consecutive annual increase in the Company's quarterly dividend. The fourth quarter dividend will be paid on November 4, 2009 to shareholders of record on October 21, 2009.
About West
West to Present at Two Upcoming Investor Conferences
LIONVILLE, Pa., Sept. 11 /PRNewswire-FirstCall/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced that Donald E. Morel, Jr., Ph.D., Chairman and Chief Executive Officer, and William Federici, Chief Financial Officer, will attend both CL King's 7th Annual Best Ideas Conference 2009, being held September 16-17, 2009 at the Omni Berkshire Place Hotel in New York City and the UBS Global Life Sciences Conference, being held September 21-23, 2009 at the Grand Hyatt Hotel in New York City.
Dr. Morel and Mr. Federici will present an overview of West's business and outlook at the CL King conference on Thursday, September 17, 2009 from 11:45 AM to 12:10 PM ET; and, at the UBS conference on September 23, 2009 from 11:30 AM to 12:00 PM ET.
A copy of the corporate presentation document as well as a live audio webcast of the presentations will be posted on the investor link of the Company's website at www.westpharma.com.
West to Host 2009 Second Quarter Conference Call
West to Host 2009 Second Quarter Conference Call
LIONVILLE, Pa., July 28 /PRNewswire-FirstCall/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced today that it will release 2009 second quarter financial results before the market opens on Tuesday, August 4, 2009 and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. To participate on the call please dial 888-790-3758 or 210-839-8398. The passcode is WST.
A live broadcast of the conference call will be available at the Company's web site, www.westpharma.com, in the "Investor" section. Please allow extra time prior to the call to visit the site and download the streaming media software required to listen to the Internet broadcast.
Form 8-K for WEST PHARMACEUTICAL SERVICES INC
--------------------------------------------------------------------------------
7-Jan-2009
Regulation FD Disclosure, Financial Statements and Exhibits
Item 7.01 Regulation FD Disclosure
On January 5, 2009, West Pharmaceutical Services, Inc. (the "Company") issued a press release announcing that William Federici, Chief Financial Officer and Michael Anderson, Vice President and Treasurer will be presenting at the 2009 CJS Securities 9th Annual "New Ideas" Summer Conference in White Plains, New York on January 7, 2009.
A copy of the Company's presentation from the conference will be available for 30 days through the Investors link at the Company's website, http://www.westpharma.com and is also attached hereto as Exhibit 99.2. A copy of the press release is attached hereto as Exhibit 99.1. Both Exhibits are incorporated herein by reference.
The information in this report (including Exhibit 99.1 and 99.2) is being furnished pursuant to Item 7.01 Regulation FD and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.
West Pharmaceutical Services Announces Quarterly Dividend
Thursday December 18, 2008, 8:00 am EST
(NYSE: WST - News) today announced that its Board of Directors approved a first quarter 2009 cash dividend of $0.15 per share. The dividend will be paid on February 4, 2009 to shareholders of record on January 21, 2009
Visit West at these events in North America.
January 17 - 18
Prefilled Syringes Forum 2008
Philadelphia, PA
West speaker: Fran DeGrazio, Vice President, Marketing and Strategic Business Development
January 21 - 23
Institute for International Research
Drug Delivery Partnerships
San Diego, CA
January 29 – 31
Medical Design & Manufacturing West
Anaheim, CA
March 26 – 28
Interphex 2008
Philadelphia, PA
March 26 – 28
PharmaMedDevice
Philadelphia, PA
April 14 – 15
Parenteral Drug Association
Annual Meeting
Colorado Springs, CO
May 11 – 15
Respiratory Drug Delivery 2008
Scottsdale, AZ
http://biz.yahoo.com/e/081106/wst10-q.html
Companies around us are crumbling and WEST is still growing....
LIONVILLE, Pa., Nov. 4 /PRNewswire-FirstCall/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced results for the third quarter of 2008. Reported diluted earnings per share of $0.40 included net after-tax income of $1.1 million, or $0.03 per diluted share, due to discrete tax benefits, net of contract settlement costs.
Consolidated Summary Results
($ millions, except per-share data ) Three Months Ended
September 30
2008 2007
Net Sales $256.2 $242.7
Gross Profit 66.0 64.3
Reported Operating Profit 17.9 12.9
Adjusted Operating Profit(1) 19.7 21.5
Reported Diluted EPS from continuing operations $0.40 $0.36
Adjusted Diluted EPS(1) from continuing operations $0.37 $0.42
(1) See corresponding notes under 'Supplemental Information and Notes to Non-GAAP Financial Measures' in the tables following the text of this release.
Sales grew despite the expected absence of revenue from several products, including components for certain anemia, or ESA, drugs, the discontinued Exubera inhalable insulin device, and certain disposable medical device components that the Company no longer produces. Together those products accounted for $14.1 million, or 5.8%, of sales, and contributed an estimated $0.10 in adjusted diluted EPS(1) in the 2007 period. Favorable currency translation and other net sales gains more than offset the effects of those sales declines, and consolidated net sales grew by 5.6% (3.9% due to currency) compared to the third quarter of 2007.
Sales price increases and other operating efficiencies contributed to a $1.7 million increase in gross profit. The consolidated gross profit margin was 25.7% in the quarter, or 0.8 percentage points lower than in the prior year quarter, due to the lower sales of higher-margin products, particularly ESA components and Exubera devices, and to raw material and other production cost increases, net of selling price increases. Adjusted operating profit(1) was $19.7 million, compared to $21.5 million in the third quarter of 2007, due to increased research and development and information systems spending, and higher stock-based compensation costs. These, together with higher net interest costs and a lower effective tax rate, contributed to quarterly adjusted diluted EPS(1) of $0.37, compared to $0.42 in the third quarter of 2007.
Executive Commentary
'We have delivered solid third quarter results in the face of known sales challenges, volatile commodity, currency and financial markets, and the seasonality that make this the least predictable quarter each year, underscoring the fundamental strength of our business and its diverse and stable product portfolio,' said Donald E. Morel Jr., Ph.D., the Company's Chairman and Chief Executive Officer. 'Putting aside the expected product-specific sales issues, like ESA drugs, other sales grew by 8% excluding currency and we are recovering most of our rising costs with price increases and cost savings from lean operations initiatives.'
'Customer orders since the close of the quarter have been encouraging and we expect to deliver year-over-year sales and earnings growth in the fourth quarter, with full year sales now expected to be approximately $1.06 billion and adjusted diluted EPS(1) of $2.38 to $2.43, or just below our earlier annual guidance,' said Dr. Morel. 'For 2009, we expect sales to grow 7% to 9% on a constant currency exchange basis and expect to improve our gross margins on an improving mix, production efficiencies and as pricing catches up with our costs.'
'It is also important for our customers, employees and shareholders to know that West is financially sound and that we intend to manage conservatively going forward. We have a growing product portfolio that serves primarily non-discretionary pharmaceutical and medical applications,' said Dr. Morel. 'We have ample liquidity, with $102.5 million of cash on hand at quarter-end and $168 million of committed, available credit in reserve. We plan to generate operating cash flow that will provide the funding required for our ongoing expansion, our new product development programs, and our dividends. We foresee no need for additional capital or refinancing before 2011. The current economic uncertainty may persist for some time, but we believe the impact on West will be marginal and we are focused on achievable strategic and financial objectives to create value for our shareholders.
LIONVILLE, Pa., Oct. 22 /PRNewswire-FirstCall/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced today that it will release 2008 third quarter financial results before the market opens on Tuesday, November 4, 2008 and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. To participate on the call please dial (888)790-3758 or (210) 839-8398. The passcode is WST
The Tech Group is a global leader in injection molding offering contract manufacturing solutions for the medical and consumer industries. Our aggressive and continual investment in technology is our commitment to reduce the time and cost of each and every phase of new product development. From design conceptualization to scale-up in support of full commercialization, The Tech Group has the experience and reputation of providing a significant and sustainable competitive advantage.
Since May 2005, The Tech Group has been a part of West Pharmaceutical Services, Inc. West, based in Lionville, Pa., is a global leader in the design and manufacture of elastomeric components and systems used for injectable drug delivery and in the design and manufacture of pharmaceutical seals.
The combined expertise in plastic component design and manufacturing of The Tech Group and West's Device Group creates one of the world's leading manufacturers of pharmaceutical delivery systems, medical devices and personal care and consumer products.
World-class facilities:
Manufacturing divisions in Arizona, Indiana, Michigan, Pennsylvania, Puerto Rico and Ireland
More than 400 injection molding machines
Clean room molding and assembly
Wealth of expertise:
Early Supplier Involvement (ESI) Team assists in product design and material exploration to ensure manufacturability
In-house mold design and construction, featuring Unigraphics 3-D, fully associative mold design and multiple CNC machining centers
Quick Response Center for developmental and prototype tooling
More than 100 CAD/CAM personnel utilizing multiple systems with the latest hardware and software technologies
High-speed automated assembly solutions
Systems and processes:
Dedicated regulatory personnel
Quality control that emphasizes SPC integration and programmable vision systems for automated part inspection
Robust Process Controls with detailed IQ, OQ and PQ procedures
The Tech Group is a West Pharmaceutical Services company
WST 42.91, +2.67, +6.6%) said it is maintaining its full-year revenue guidance at $1 billion and its full-year earnings guidance in the range of $2.27 a share and $2.37 a share. The Lionville, Pa., packaging company expects to recognize, in the third quarter, a net discrete tax charge of up to 6 cents a share as a result of changes in its estimates of tax obligations not related to current year operating results.
<a href="http://s360.photobucket.com/albums/oo43/christerina/?action=view¤t=IMG_0152.jpg" target="_blank"><img src="http://i360.photobucket.com/albums/oo43/christerina/IMG_0152.jpg" border="0" alt="Like father like son at FT Desoto park"></a>
West Increases Quarterly Dividend
LIONVILLE, Pa., Sept. 22 /PRNewswire-FirstCall/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced that its Board of Directors approved an increase in its fourth quarter cash dividend to $0.15 per share, an increase of one cent, or 7.1%, over the previous quarter. It is the sixteenth consecutive annual increase to the dividend. The dividend will be paid on November 5, 2008, to shareholders of record on October 22, 2008
Board Portal Enables the Move Towards Paperless
MENLO PARK, CA -- (Marketwire) -- 08/20/08 -- West Pharmaceutical Services, Inc. (NYSE: WST), a leader in developing delivery systems that enhance the administration of pharmaceuticals, has adopted use of BoardVantage to distribute board materials electronically and reduce their printing requirements. West Pharmaceutical Services will be using BoardVantage not only to support their board members, but also to collaborate with outside auditors and executive staff.
Global Specialty & Generic Pharmaceuticals Conference
LIONVILLE, Pa., May 21 /PRNewswire-FirstCall/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced that William Federici, Chief Financial Officer and Michael Anderson, Vice President and Treasurer will be presenting at the 2008 UBS Global Specialty & Generic Pharmaceuticals Conference at 11:30 a.m. GMT on May 28, 2008 in London.
A copy of the corporate presentation document will be posted on the investor link of the Company's website at www.westpharma.com and the live audio webcast of the presentation will also be available through the website. A replay of the audio portion will be accessible on the Company's website beginning 3 hours after the actual presentation time and will be available until June 11, 2008.
Management is very pleased with the quarter overall, because the rest of the businesses came through with stronger than anticipated results, leading to earnings of $0.76 per diluted share, $0.72 after removing some items that might complicate comparisons to other periods. Gross margins were solid at 30.8%, although slightly lower than the 31.2% reported for the first quarter of 2007. We had no expectation that it would equal or exceed last year's all-time record first quarter. However, the consolidated results get 2008 off to a very good start.
West Announces Third Quarter 2008 Dividend
PR Newswire - May 07, 2008 11:00 AM ET
Related Quotes
Symbol Last Chg
WST Trade 46.17 +0.46
Quotes delayed at least 15 minutes
West Pharmaceutical Services, Inc. (NYSE: WST) today announced that its Board of Directors approved a third quarter 2008 cash dividend of $0.14 per share. The dividend will be paid on August 6, 2008 to shareholders of record on July 23, 2008.
West Pharm beats by $0.03, reports revs in-line; guides FY08 EPS in-line
Briefing.com - May 01, 2008 7:05 AM ET
Related Quotes
Symbol Last Chg
WST Trade 46.27 +0.17
Quotes delayed at least 15 minutes
Reports Q1 (Mar) earnings of $0.72 per share, excluding non-recurring items, $0.03 better than the First Call consensus of $0.69; revenues rose 5.1% year/year to $270.7 mln vs the $268.1 mln consensus. Co issues in-line guidance for FY08, sees EPS of $2.40-2.50 vs. $2.46 consensus; sees FY08 revs of $1.08 bln vs. $1.06 bln
May 1 (Reuters) - West Pharmaceutical Services Inc (WST.N: Quote, Profile, Research), a maker of pharmaceutical packaging components, posted better-than-expected first-quarter profit, helped by favorable foreign currency translation.
The company earned $26.2 million, or 76 cents a share, compared with $26.5 million, or 77 cents a share, in the year-ago period.
Excluding several one-time items, the company earned 72 cents a share in the latest quarter.
Revenue rose 5 percent to $270.7 million for the quarter. Currency translation contributed 6.3 percent of sales growth.
Excluding currency translation effects, pharmaceutical systems segment sales grew at 0.7 percent, and tech group segment sales declined by 5.9 percent. Both segments' sales were affected by expected sales declines, the company added.
Analysts on average were expecting earnings of 69 cents a share, before items, on revenue $262 million, according to Reuters Estimates.
The company also raised its 2008 forecast to reflect revised exchange rates.
The company now expects to earn $2.40 to $2.50 a share before items, on revenue of $ 1.08 billion. Analysts average forecast is earnings of $2.46 a share on revenue of $1.06 billion.
West Pharmaceutical shares closed at $46.91 Wednesday on Nasdaq. (Reporting by Jennifer Robin Raj in Bangalore; Editing by Amitha Rajan)
© Thomson Reuters 2008 All rights reserved
I will have more updates comming soon.In two weeks I will be on here regularly.wink wink
Talked with more employees,working almost every saturday AND sunday here in florida,,
Took a small interest in this company today.Couple of factories here in my city.Employees working more overtime than they can handle...Looks good for future revenues/profits.Been hiring for multiple positions for weeks now.
Followers
|
2
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
95
|
Created
|
04/04/08
|
Type
|
Free
|
Moderators |
http://www.westpharma.com/en/Pages/Default.aspx
http://www.westpharma.com/en/about/Pages/GlobalFacilities.aspx
http://www.pharmaasia.com/2015/04/eric-green-is-new-ceo-at-west-pharma/
-----PLEASE NOTE--------
THIS IS NOT A DAY TRADE STOCK
THIS STOCK HAS AVERAGED 28% PER YEAR FOR 10 YEARS STRAIGHT
2013 2 for 1 stock split
2004 2 for 1 stock split
West Pharmaceutical Services, Inc. manufactures components and systems for injectable drug delivery and plastic packaging, and delivery system components for the healthcare, personal care, and consumer products markets. The company operates in two segments, Pharmaceutical Systems and Tech Group. The Pharmaceutical Systems segment engages in the design, manufacture, and sale of various elastomer, metal, and plastic components used in parenteral drug delivery for the pharmaceutical, generic, and biopharmaceutical industries. It offers various pharmaceutical packaging components, such as stoppers and discs, plungers, seals, dropper bulbs, needle shields and tip caps, and sterile devices. This segment also provides contract analytical laboratory services for testing and evaluating primary drug packaging components. The Tech Group segment produces injection molded components and devices, such as contact lens storage kits, pill dispensers, and disposable blood collection systems for surgical, ophthalmic, diagnostic, and drug delivery systems. This segment also involves in the manufacture and assembly of systems and devices used for nasal, oral, pulmonary, and injectable delivery of drugs used to treat diseases. The company's customers include pharmaceutical, biotechnology, generic drug, and medical-device producers. West Pharmaceutical sells its products primarily in the United States,Asia,Germany,France,and other European countries. It markets its products and services principally through its own sales force and distribution network, as well as through sales agents and distributors. The company was founded in 1923 and is headquartered in Lionville, Pennsylvania.
West Pharmaceutical Services Inc.'s Corporate Governance Quotient (CGQ®) as of 1-Apr-08 is better than 97.2% of S&P 600 companies and 97.9% of Health Care Equipment & Services companies.
Improving Global Healthcare
West helps improve the safe delivery of pharmaceutical, health care and personal care products. Media Relations Contact for North and South America
Second Quarter 2016 Highlights
"Adjusted diluted EPS" and "net sales at constant currency" are Non-GAAP measurements. See discussion under the heading "Non-GAAP Financial Measures" in this release.
Executive Commentary
"We had a successful quarter with solid organic sales growth, increased gross and operating profit margins and new product launches and approvals," said Eric M. Green, President and Chief Executive Officer. "Led by our Commercial group, both the Proprietary Products and Contact-Manufactured Products segments contributed to overall organic sales growth, with broad-based growth in all three market units of Biologics, Generics and Pharma. We continue to see double-digit sales growth in our high-value product offerings including Westar RS® and Westar RU®, Daikyo®, FluroTec® and NovaPure® components."
"We had another strong quarter of gross margin expansion fueled by high-single digit organic sales growth, favorable product mix and operational efficiencies. I am pleased that our Global Operations initiatives are successfully increasing throughput and reducing lead times. As a result, we saw a sequential quarterly reduction in backlog levels and remain on track with our target of achieving faster lead times in the second half of the year and reducing backlog levels that better match underlying demand."
"Earlier this month, the U.S. Food and Drug Administration (FDA) approved the first combination product that incorporates an injectable drug with West's SmartDose® technology for use in the United States. This milestone exemplifies West's strategy of providing the highest quality components and systems to meet our customers' needs for injectable drug delivery solutions; in this case, an integrated containment system that combines the novel SmartDose device with a Daikyo Crystal Zenith® container and a Flurotec® piston. I am proud of the work of our Innovation and Technology team and partners to achieve this milestone. The many years of work and dedication to this project have paved the way for new opportunities for the on-body delivery of injectable drugs."
Mr. Green concluded, "Since the launch of our market-led strategy and business realignment at the start of the year, our teams have performed well, and the company is well positioned for future success. We continue to see solid end-market demand in our Proprietary Products segment and expect to see higher organic sales growth in our Contract-Manufactured Products segment in the second half of the year. With these trends, we are raising our full-year 2016 organic sales growth guidance to a new range of between 7% and 9% and are raising the lower-end of our adjusted diluted EPS guidance
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |